Gujarat hits 90% HPV vaccine target

• Gujarat vaccinates 90% of eligible teenage girls against HPV
• Over 5 lakh girls received the Gardasil-4 vaccine in 34 districts
• 14-year-old girls can access the vaccine at state health centres

Gujarat has marked a major public health success, vaccinating 90% of eligible teenage girls against HPV. Learn about the widespread campaign and the vaccine's proven safety.

Impressive Vaccination Drive

Gujarat has successfully administered the Human Papillomavirus (HPV) vaccine to an impressive 5 lakh girls, thereby hitting a remarkable 90% of its target under the national vaccination program. This significant public health initiative, aimed at protecting adolescent girls, identified 5,43,483 eligible individuals within the state. The campaign was strategically rolled out, commencing on February 28 and expanding across more than 2,200 health centers spread throughout 34 districts and 8 major urban areas of Gujarat. The drive officially began its operational phase on March 2, demonstrating a swift and efficient execution of the public health mandate.

Safety and Accessibility Highlighted

The effectiveness and safety of the HPV vaccination drive in Gujarat have been strongly emphasized by Health Minister Praful Pansheriya. He proudly stated that the campaign, operating under the guidance of Chief Minister Bhupendra Patel, has achieved substantial success without a single report of serious adverse side effects, underscoring the vaccine's complete safety profile. For all 14-year-old girls in Gujarat, the vaccine is readily accessible. It is available at a comprehensive network of healthcare facilities, including all medical college-affiliated hospitals, district hospitals, sub-district hospitals, and community health centers (CHC), primary health centers (PHC), and urban primary health centers (UPHC) across the state, ensuring widespread reach.

Understanding the Vaccine

The vaccine being utilized in India's national HPV vaccination program is Gardasil-4, a quadrivalent formulation developed by MSD India. This specific vaccine is designed to offer protection against four key types of the Human Papillomavirus: HPV types 16 and 18, which are the primary culprits responsible for causing cervical cancer, and HPV types 6 and 11. By targeting these specific high-risk strains, the vaccine plays a crucial role in preventing HPV infections and the subsequent development of HPV-related cancers and diseases, particularly among young women.